Effect of Certolizumab Pegol on Multiple Facets of Psoriatic Arthritis as Reported by Patients: 24‐Week Patient‐Reported Outcome Results of a Phase III, Multicenter Study

Publisher： John Wiley & Sons Inc

E-ISSN： 2151-4658|66|7|1085-1092

ISSN： 2151-464x

Source： ARTHRITIS CARE AND RESEARCH, Vol.66, Iss.7, 2014-07, pp. : 1085-1092

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Impact of Certolizumab Pegol on Patient‐Reported Outcomes in Patients With Axial Spondyloarthritis

By  

ARTHRITIS CARE AND RESEARCH, Vol. 2151-464X, Iss. 10, 2015-10 ,pp. : 1475-1480

John Wiley & Sons Inc

Access to resources Recommend Favorite

Impact of Certolizumab Pegol on Patient‐Reported Outcomes in Patients With Axial Spondyloarthritis

By  

ARTHRITIS CARE AND RESEARCH, Vol. 67, Iss. 10, 2015-10 ,pp. : 1475-1480

John Wiley & Sons Inc

Access to resources Recommend Favorite

Effect of Certolizumab Pegol Over Ninety‐Six Weeks in Patients With Axial Spondyloarthritis: Results from a Phase III Randomized Trial

By  

ARTHRITIS & RHEUMATOLOGY, Vol. 67, Iss. 3, 2015-03 ,pp. : 668-677

John Wiley & Sons Inc

Access to resources Recommend Favorite

Tofacitinib With Methotrexate in Third‐Line Treatment of Patients With Active Rheumatoid Arthritis: Patient‐Reported Outcomes From a Phase III Trial

By  

ARTHRITIS CARE AND RESEARCH, Vol. 67, Iss. 4, 2015-04 ,pp. : 475-483

John Wiley & Sons Inc

Access to resources Recommend Favorite

Choosing a patient-reported outcome measure

By McClimans Leah  

Theoretical Medicine, Vol. 32, Iss. 1, 2011-02 ,pp. : 47-60

Springer Publishing Company

Access to resources Recommend Favorite